Instagram story viewer> @rightsandreasonproject> Tagged

Robert

@rightsandreasonproject

212

followers

133

following

The Rights and Reason Project is an advocacy initiative defending cognitive liberty, bodily autonomy, and evidence-based drug policy.

POSTS STORIES REELS TAGGED

Horizons NY 2026 🗽 | New York Academy of Medicine | October 15-17 ✨

I was elated to attend Horizons on Friday + Saturday to gather in community and support @ssdpofficial & @globalpsychedelicsociety.

As a co-steward of @tripspgh, it was lovely to meet with other society leaders at our GPS lunch. As a board member for #SSDP, I enjoyed sharing details of our dedicated drug policy work with guests, and am so grateful for @astrophyzixboi, @jorgehvalderrabano, + @jollygreengiant.420 for managing booths at the conference + after party.

I had such an incredible time at @psychedelic_assembly + @cannademix’s Harlem Hang on Friday followed by @brooklynpsychedelicsociety + @chacruna.institute’s ECSTATIC BLOOM on Saturday. My heart was with @urbanindigenouscollective as well—their event looked incredible. I wish I could have been everywhere at once!

Our community showed up HUGE on Horizons weekend. I’m looking forward to gathering in Denver this Spring for @psychedelicscience. Can’t wait to be together again with the community that I love so much! ♥️🌸

66

0

The DEA wants to shut down crucial medical research by criminalizing 5 Tryptamines including two drugs in clinical trials, one of which has been given Breakthrough Therapy Designation by the FDA for the treatment of postpartum depression — in direct opposition to President Trump’s executive order on psychedelics!

SSDP, the Rights & Reason Project, and Mindstate Design Labs have teamed up to take the DEA to court and stop research harm!

3

19

This week’s @psychedelicamericas Sunday Sound-Off is live 🔊

📌 “The Miracle Has Fine Print”: Texas has passed a law for iboga*ne trials, Washington has promised $50M, and FDA has a docket open until Nov. 20. Epidemiologist Odette Alina Hauke — former Associate Director of Regulatory Affairs for @ataibeckley — asks the question nobody has written into the contracts yet: who gets to check the safety data?

📌 Later this month: The D.C. Psychedel*c Professionals Mixer is back. Saturday, Oct. 24, at Higher Ground D.C. (@hgroundofficial) — presented in partnership with @ritualandreefer, @psychedelicbarassociation, @psychedelicstoday, @lucidnewspsychedelics, @decrimnaturerva, and more!

📌 PSA NewsWire Highlights of the Week, with reporting and op-Ed’s from The Idaho Capital Sun, @doubleblindmag, @psychedelicstoday and @marijuanamoment

Read the full issue at the link in bio 🔗
Psychedel*cAmericas.Org

#SundaySoundOff #Ibogaine #DrugPolicy #FDA

3

7

FOR IMMEDIATE RELEASE: The public has until Oct. 23 to tell the DEA why they should stop criminalizing psychedelic research that could save lives. SSDP’s new public comment tool makes it easy to make your voice heard! 📢

https://ssdp.org/blog/dea-schedule-i-proposal-would-criminalize-compound-with-breakthrough-therapy-status-for-postpartum-depression/

41

0

The FDA moves forward. The DEA moves backward. 🧭

Just one week after a historic FDA public hearing on the future of psychedel*c medicine, the DEA formally published an order to place obscure five tryptam*nes into Schedule I:

🔹 4-0H-D*PT
🔹 5-Me0-AMT
🔹 5-Me0-M*PT
🔹 5-Me0-DET
🔹 D*PT

The DEA’s own record doesn’t make its case:
📉 0 deaths from single-substance exposures across 65 cases over 18 years (2003–2021)
📉 518 law enforcement encounters cited, with no timeframe given
📉 HHS notes the FDA is “not aware of any diversion from research or legitimate manufacturing activities”

The collision: the FDA gave Reunion Neurosciences a Breakthrough Therapy designation for a 4-OH-DiPT candidate to treat postpartum depression. The DEA wants that same compound in Schedule I, legally defined as having “no currently accepted medical use.”

“One foot steps on the gas while the other steps on the brake, and the taxpayers are left to pay for this whole mess.” — Robert Rush, Esq., Rights and Reason Project

Watch the video for the breakdown, swipe to learn more, then read the full story online at Psychedel*cAmericas.Org — including all the details about the 2022 legal fight that stopped the DEA’s last attempt, at the link in bio 🔗

Where do you stand: should federal drug scheduling wait for the science? Tell us below 👇

3

13

“The FDA really took the word ‘hearing’ literally.” 🗣️🍄

In a milestone event for the future of mental health, the FDA recently hosted a public hearing on the therapeutic use of psychedel*cs drugs. But instead of top-down mandates, the event was driven by the public!

@psychedelicamericas’ latest guest column by Dr. Alaina Jaster (produced in partnership with @psychedbrainsci) explores the biggest takeaways from the hearing.

Over 80 selected speakers stepped up to address the open questions surrounding:

✅ Provider training & credentialing
✅ Protecting patient safety
✅ Ensuring equitable access
✅ Data collection

As psychedel*cs move closer to mainstream medicine, who is making the rules? Tap the link in our bio to read the full breakdown! 🔗

3

1

Have you seen the new @psychedelicamericas ?

If not, allow us to reintroduce ourselves…

@psychedelicamericas is a nonprofit-sponsored independent news organization dedicated to rigorously independent psychedel*c news, commentary, education, and analysis across the United States and around the world.

We work closely with your favorite psychedel*c news outlets: @psychedelicstoday, @doubleblindmag, @lucidnewspsychedelics, @talking.drugs, @marijuanamoment and institutional leaders like @psychedelicbarassociation, @globalpsyweek, @workinpsydelic, the @psychedelicwritersguild and more to foster collaborative reporting practices, curate dynamic next-gen media coverage on all things modern psychedel*a, and empower the next generation of psychedel*c discourse, one story at a time.

Subscribe to @psychedelicamericas today! 🔗 in bio

3

1

Is Massachusetts going too far with its new kratom crackdown? 🎙️🌿

This morning, @psychedelicamericas founder Jack Gorsline joined @gbhnews’ Tori Bedford (@tori_bedford)to unpack the state’s controversial move to classify kratom as a Schedule I drug — putting the natural leaf in the exact same legal category as heroin.

During the interview, Gorsline highlighted the growing friction between sweeping state criminalization and public health evidence: “Advocates aren’t necessarily asking for a free-for-all. They’re arguing that the state is using a sledgehammer here where a scalpel was needed — criminalizing the natural leaf rather than regulating these potent synthetics and other products.”

While the state pushes ahead with prohibition, Gorsline points out that a Schedule I designation ignores kratom’s active use by many for treating severe anxiety and substance use disorder. It also directly contradicts guidance from major health organizations like the @amermedicalassn, @who,, and the @unitednations, which all advocate for the decriminalization and regulation of drugs for personal possession.

Hit the link in @psychedelicamericas’ bio to listen to the full interview and get the complete breakdown of the battle over kratom in Massachusetts! 🎧👇

3

0

🌿 Dive into the research that launched the modern psychedel*c era with the latest from The Psychedel*c Bookshelf, powered by @psychedelicamericas and The @psychedelicwritersguild ! 🌿

First, head to Psychedel*cAmericas.Org to check out Chronicles of Kykeon (@kykeon53) founder Jim Tate’s comprehensive review of DMT: The Spirit Molecule. Tate unpacks Dr. Rick Strassman’s sober clinical report on the first legal human psychedelic research project conducted in the United States in a generation, which began in 1990. The review explores the grueling bureaucratic approval process, the famous “entity” trip reports from the sixty volunteers, and the honest reality of why Strassman ultimately shut his own studies down in 1995.

Then, be sure to check out TPBS host Jim Tate as he sits down for an exclusive interview with Dr. Strassman! Together, they delve into the science and the mysteries behind DMT, exploring how this powerful molecule is reshaping our understanding of consciousness and spirituality.

Whether you’re a seasoned psychonaut or new to the topic, this paired review and interview offer insights that challenge conventional thinking and provide a comprehensive look at the potential of psychedel*cs in modern society.

👉 Read the full interview at the link 🔗 in The PWG’s bio , and be sure Subscribe to PSA at PsychedelicAmer*cas.Org to get the latest installments of The Psychedel*c Bookshelf delivered right to your inbox every two weeks!

3

2

Does decriminalizing psychedel*cs actually make communities safer? The data says yes. 🛑✨

A peer-reviewed study published in Social Sciences analyzed the real-world impact of psychedel*c decriminalization - and the results directly challenge historical fears that reform would destabilize communities. Far from causing a “wild west,” ending punitive laws has functioned as a powerful, evidence-backed strategy for harm reduction and community health.

Here is what the survey of residents in decriminalized zones revealed:

    📈 84.0% of participants reported clear improvements in safety, social acceptance, product quality, or legal risks.

    🧠 Nearly 75% experienced decriminalization-related improvements regarding psychedel*c therapy.

    💊 Over 27% stopped or reduced their use of traditional pharmaceutical medications due to psychedel*d decriminalization.

    📉 Only 5.5% reported worsened conditions in any category—and not a single participant reported that legal risks had worsened.

Swipe 👉🏼 to see how modern drug policy reform is changing lives, reducing legal anxiety, and opening new pathways for mental health and community-led healing.

🔗 Read the full investigative article online at the link in @psychedelicamericas bio!

3

0

Pittsburgh, thank you for being good to us. A magical time was had. 🙌🏼

48

4

🚨 We have just TWO DAYS to stop the criminalization of SR-17108 🚨

Every story shared reminds us what’s at stake.

People across the country are telling us how SR-17018 has given them hope when other options failed. These aren’t abstract policy debates — they’re real lives, real families, and real futures.

On July 31, the DEA will ban SR-17018, putting promising research and future access at risk — unless we stop them.

If these stories move you, take two minutes to make your voice heard. Send a letter to Congress and urge lawmakers to protect research and oppose this ban.

Together, we can make sure hope isn’t outlawed.

📢 Use the link in our bio to send your letter now!

3

0